Revelstoke Capital Partners



Denver, CO – Schryver Medical Sales and Marketing, LLC (“Schryver”), a portfolio company of Revelstoke Capital Partners (“Revelstoke”), a Denver-based private equity firm, has completed the acquisitions of Community Portable X-Ray, Inc. (“Community”) and MetroStat Clinical Laboratory, Inc. / MetroStat Diagnostic Services, Inc. (collectively, “MetroStat”). These acquisitions mark Schryver’s entrance into the Texas market.

Schryver, headquartered in Denver, Colorado, is a JCAHO accredited provider of mobile imaging diagnostics, clinical laboratory services, oxygen therapy and durable medical equipment rental. Schryver serves more than 3,500 long term post-acute facilities, assisted-living centers, and skilled nursing facilities, as well as numerous homecare patients. Schryver’s significant value proposition and service line diversity have resulted in long term customer relationships and a superior brand reputation. Since Revelstoke’s investment in Schryver, the company has completed six acquisitions, with these latest two following Schryver’s January 2015 acquisition of Nashville-based Quality Mobile X-Ray and its July 2015 acquisitions of Main Street Clinical Laboratories, On-Site Imaging Services, and B.O.N. Clinical Laboratories.

Community Portable X-Ray, Inc. is a provider of mobile x-ray and other imaging services based in Plano, Texas, with branch locations in Fort Worth, Houston, and San Antonio, Texas. The company provides mobile x-ray and EKG exams to long-term health care facilities, home care, psychiatric hospitals, industrial sites, dialysis centers and athletic teams.

Based in Garland, Texas, MetroStat is a provider of clinical laboratory services, mobile X‐ray, and other mobile imaging services in the state of Texas. MetroStat uses innovative, state-of-the-art equipment in the field. Its 100% digital ultrasound and EKG teleradiology equipment allow its technologists to obtain the best images possible for interpretation by its radiologists. In addition to operating the latest imaging equipment, MetroStat’s clinical laboratory and in-house microbiology system were recently built out utilizing cutting edge hospital grade lab equipment.

“We are excited to expand our operations into Texas,” said Doug Goetz, CEO of Schryver. “Rapid response times combined with the highest quality diagnostic services are critical to our customers, and adding Community and MetroStat’s significant resources allows us to better serve our current and new customers in Texas. This transaction serves as an important step in our continued effort to bring Schryver’s superior medical diagnostic services to this rapidly expanding industry across the U.S.”

“The Schryver management team continues to execute on its strategy of becoming a leading national provider through a disciplined buy and build approach,” commented Mark King, CEO, Managing Partner and Co-Founder of Revelstoke. “Schryver has now completed six acquisitions since our investment expanding the company’s reach into 16 states.”

Perkins Coie LLP and Winston & Strawn LLP acted as legal advisors to Schryver.

About Schryver

Based in Denver, Colorado, and employing more than 1,000 professionals, Schryver is a leading provider of mobile imaging, clinical laboratory, and oxygen therapy equipment outsourcing across sixteen U.S. states serving the long term care market, hospitals, assisted-living centers, and homecare patients.

About Revelstoke

Revelstoke is a private equity firm formed by experienced investors who focus on building exceptional industry-leading companies. Revelstoke strives to partner with management teams to execute on a disciplined organic and acquisition strategy to build industry-leading companies and generate superior investment returns for management owners and investor partners. Revelstoke’s Managing Partners, Mark King, Dale Meyer and Simon Bachleda, have more than six decades of combined private equity investing and capital formation experience having completed more than 100 platform and add-on acquisitions, representing more than $6 billion of total enterprise value.